CPC C07K 16/468 (2013.01) [A61K 35/17 (2013.01); A61K 47/6879 (2017.08); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C12N 5/16 (2013.01); C12N 15/62 (2013.01); C12N 2510/00 (2013.01)] | 16 Claims |
1. An ex vivo or in vitro method of generating a modified T cell, comprising introducing into a T cell a composition comprising
(a) a first RNA molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain, a transmembrane domain, and a CD3 zeta signaling domain; and
(b) a second RNA molecule encoding a bispecific antibody, wherein the bispecific antibody comprises a first antigen recognition domain that recognizes the same antigen as the antigen binding domain of the CAR, and a second antigen recognition domain that recognizes CD3 wherein the bispecific antibody encoded by the second RNA molecule is secreted by the cell.
|